The First Precision Oncology Forum at SMC:

Today's Cancer Research for Tomorrow's Cancer Cure

QR코드

일시 2023년 3월 31일(금) 13:00~ (등록 12:30~)

장소 삼성서울병원 암병원 B1 강당

*온라인 동시 진행 (http://smc-opc.kr/)

등록비 무료

연수평점 3점

사전등록기간 3월 13일(월) ~ 3월 29일(수)

TIME	TOPIC	CHAIR / SPEAKER
13:00~13:10 (10)	Welcome Messages from SMC leadership	SeungWoo Park President, Samsung Medical Center Kyu-Sung Lee Director, Research Institute For Future Medicine Samsung Medical Center Wooyong Lee Executive Vice President SMC & General Director, Cancer Center Samsung Medical Center
Session I (13:10~13:30)	Overview	Hee Cheol Kim Chief Strategy Officer, Samsung Medical Center
13:10~13:15 (5)	SMC Precision Medicine Program: our 10-year journey	Joon Oh Park Director, Innovative Institute for Precision Medicine Samsung Medical Center
13:15~13:30 (15)	Overview of Cancer Precision Medicine: a new era yet to come	Jung Yong Hong Hematology / Oncology Samsung Medical Center
Session II (13:30~14:45)	For our cancer patients with NGS technology	Young-Hyuck Im Former Director, RIFM, Samsung Medical Center Kyoung-Mee Kim Director, Center for Experimental Pathology Samsung Medical Center
13:30~13:55 (25)	Bringing Science into the patients: the cell-free DNA journey	AmirAli Talasaz Co-founder and President Guardant Health Inc, USA
13:55~14:15 (20)	Neoantigen targeted therapeutic vaccination	Soonmyung Paik Theragenbio, Korea the First Director, IIPM, Samsung Medical Center
14:15~14:35 (20)	Precision Oncology Center at SMC: a 10-year journey and what is next?	Jeeyun Lee Director, Precision Oncology Center Director, Experimental Therapeutics Development Center Samsung Medical Center
14:35~14:45 (10)	Coffee Break	
Session III (14:45~16:35)	For our cancer patients with emerging drugs and biotechnologies	Joon Oh Park Director, IIPM, Samsung Medical Center Yong Han Paik Hepatology, Samsung Medical Center
14:45~15:05 (20)	Al driven multiplex proteomics to predict response to immunotherapy	Yoojeong Heo Senior Research Engineer, Neocella
15:05~15:25 (20)	Patient-derived organoids as a potential model to predict response to immunotherapy	Bo Sung Ku MBD (Medical& Bio Decision) CO. Ltd.
15:25~15:45 (20)	AZ drug development for oncology unmet needs	Viia Valge-Archer Senior Director, Scientific and Clinical alliances, External R&D, Oncology R&D, Astra Zeneca, UK
15:45~16:05 (20)	Advancing the MSD oncology pipeline to address patient unmet medical needs	Andrea LAUER Asia-Pacific Oncology Lead, Global Medical Affairs MSD, Singapore
16:05~16:20 (15)	Plasma proteomics for early detection and treatment response	Rocky Choi Director of Olink, USA
16:20~16:35 (15)	Facilitating Precision Oncology with Metabolomics: Expanding Applications in Cancer Care	Natasa Giallourou Field Metabolomics Scientist Metabolon Inc., USA

*상기 일정은 내부사정 상 변동될 수 있음



